Hikma Pharmaceuticals
As of the edition of 20 October 2026, Hikma Pharmaceuticals runs 53 drugs, 53 of them marketed; it is on route A at 0 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
- West-Ward Pharmaceutical: acquired in 1990; successor HIKMA PHARMACEUTICALS
- Roxane Laboratories: acquired in 2016; successor HIKMA PHARMACEUTICALS
Drugs by status
| Status | Count |
|---|---|
| Marketed | 53 |
| Total | 53 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cyclophosphamide anhydrous | none listed | 0 |
| Prednisone | none listed | 1 |
| Acetaminophen | none listed | 17 |
| Fentanyl | none listed | 6 |
| Oxytocin | none listed | 1 |
| Morphine | none listed | 2 |
| Daunorubicin | none listed | 2 |
| Caffeine | none listed | 12 |
| Oxycodone | none listed | 2 |
| Metronidazole | none listed | 0 |
| Vancomycin | none listed | 0 |
| Naloxone | none listed | 10 |
| Colchicine | none listed | 8 |
| Digoxin | none listed | 0 |
| Furosemide | none listed | 2 |
| Heparin | none listed | 5 |
| Phenylephrine | none listed | 6 |
| Clonidine | none listed | 0 |
| Methadone | none listed | 2 |
| Glycopyrronium | none listed | 10 |
| Pantoprazole | Ends 2027 (exclusivity) | 1 |
| Levothyroxine | none listed | 6 |
| Hydromorphone | none listed | 1 |
| Voriconazole | none listed | 0 |
| Palonosetron | none listed | 3 |
A route B row is one company at one target. 28 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 0 targets, route B at 5 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Hikma Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 1 trials led